Skip to content
The Nexus
DossierENTITY

Opdivo

Coverage of Opdivo in the Nexus archive.

Earliest in view: Jul 28 · 13:39 UTCMost recent: Aug 2 · 21:27 UTC
Co-mentioned in this coverage
AstraZenecaorganization1Bristol Myers Squibborganization1Eliquistopic1Breyanzitopic1Opdualagtopic1Camzyostopic1Food and Drug Administrationorganization1Replimuneorganization1RP1topic1PD-1-inhibitortopic1
Recent coverage
  • BUSINESSAug 2 · 21:27 UTCFORTUNE
    AstraZeneca said to have explored Bristol Myers merger

    AstraZeneca Plc explored an acquisition of Bristol Myers Squibb Co., which could create one of the world's largest drugmakers. Bristol Myers Squibb, with a $133 billion market capitalization, faces patent losses for key drugs like Eliquis and Opdivo, while AstraZeneca has a market value of about £196 billion. Bristol recently reported record quarterly sales of $13 billion driven by newer treatments.

  • HEALTHJul 28 · 13:39 UTCSTAT NEWS
    STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment

    FDA staff have reiterated concerns about insufficient data to support approval of Replimune’s investigational skin cancer treatment RP1. The agency criticized a single-arm trial combining RP1 with Opdivo, arguing it fails to establish the drug’s efficacy or systemic benefits, while Replimune claims ethical and feasibility challenges prevent a placebo-controlled study.